Rhenman & Partners Asset Management Ab Horizon Therapeutics Public LTD CO Transaction History

Rhenman & Partners Asset Management Ab

13 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2022 Nov 14, 2022	SELL	$58.92 - $84.67 $11.5 Million - $16.5 Million	-195,299 Reduced 60.04%	130,000 $8.1 Million
Q2 2022 Aug 12, 2022	SELL	$79.4 - $116.36 $836,717 - $1.23 Million	-10,538 Reduced 3.14%	325,299 $25.9 Million
Q1 2022 May 13, 2022	SELL	$86.42 - $109.81 $7.71 Million - $9.79 Million	-89,163 Reduced 20.98%	335,837 $35.3 Million
Q4 2021 Feb 11, 2022	SELL	$98.56 - $119.91 $4.44 Million - $5.4 Million	-45,000 Reduced 9.57%	425,000 $46 Million
Q3 2021 Nov 12, 2021	SELL	$91.91 - $110.37 $5.06 Million - $6.07 Million	-55,000 Reduced 10.48%	470,000 $51.5 Million
Q2 2021 Aug 13, 2021	SELL	$86.24 - $95.92 $6.04 Million - $6.71 Million	-70,000 Reduced 11.76%	525,000 $49.2 Million
Q1 2021 May 14, 2021	SELL	$71.83 - $95.48 $359,150 - $477,400	-5,000 Reduced 0.83%	595,000 $54.8 Million
Q4 2020 Jan 19, 2021	SELL	$67.0 - $84.39 $6.37 Million - $8.02 Million	-95,000 Reduced 13.67%	600,000 $43.9 Million
Q3 2020 Oct 13, 2020	SELL	$55.23 - $79.93 $3.04 Million - $4.4 Million	-55,000 Reduced 7.33%	695,000 $54 Million
Q2 2020 Jul 16, 2020	SELL	$30.2 - $56.98 $7.55 Million - $14.2 Million	-250,000 Reduced 25.0%	750,000 $41.7 Million
Q1 2020 Apr 16, 2020	BUY	$24.87 - $38.56 $5.6 Million - $8.68 Million	225,000 Added 29.03%	1,000,000 $29.6 Million
Q4 2019 Jan 17, 2020	SELL	$25.43 - $36.67 $6.36 Million - $9.17 Million	-250,000 Reduced 24.39%	775,000 $28.1 Million
Q3 2019 Oct 16, 2019	BUY	$23.0 - $27.97 $23.6 Million - $28.7 Million	1,025,000 New	1,025,000 $27.9 Million

2.07M

20K

Ticker HZNP
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—General
Shares Outstandng 230,384,000
Description
Horizon Therapeutics Public Limited Company, a biotechnology company, focuses on the discovery, development, and commercialization of medicines that address critical needs for people impacted by rare, autoimmune, and severe inflammatory diseases. The company operates in two segments, Orphan and Inflammation. Its portfolio comprises 12 medicines ...

Get notified when there are updates to the investment portfolio of Rhenman & Partners Asset Management Ab, based on Form 13F filings with the SEC.

Stay updated on Rhenman & Partners Asset Management Ab with notifications on news.